Zymeworks Inc.
- ZYME
- NASDAQ
- Biotechnology
- Cancer/Oncology
- Bispecific Antibodies
- Clinical-Stage Biotech
$25.03
Today −2.80%Quote Oct 16, 2026, 08:00 PM UTC
−8.92%over the last month
Max drawdown −10.2%From 1-month high −9.2%3 months +5.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.80B
Quote Oct 16
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$41.40
+65.4% from here
Floor
$25.01
0.1% below price
Where the price sits
22 analysts
Analyst range, low to high
$32.00$55.00
- Price $25.03
- Resistance $25.80–$26.06
- Consensus $41.40
The price is just above its floor. Analysts' average target sits about 65% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ZYMEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $4.6M
- Royalty$1.6M34.6%
- Research Support Payments And Other Service$291,0006.3%
- Other / not reported$2.7M59.0%
Industry
Biotechnology
Employees
231